One month after approval, a handful of payers — including Anthem — have adopted policies taking a more cautious stance than what the FDA set out in the gene therapy's label.
Source: Healthcare Dive, https://www.healthcaredive.com
MedBiz Pro > Vesti svet > Zolgensma set a new drug pricing bar. Insurers show some signs of pushback